Proteoglycans regulate protein tyrosine phosphatase receptor - sigma organization on hematopoietic stem/progenitor cells
Hematopoietic stem cell transplantation is utilized in the curative therapy of thousands of patients with hematologic malignancies and blood dyscrasias annually [1]. In the United States, only 16 – 75% of all patients who meet an indication for an allogeneic HSC transplant will have an HLA-matched sibling or matched unrelated donor available [2]. In such patients, alternative donor HSC transplantation can be performed, utilizing either human cord blood or haploidentical related donors [3-8 ]. In both cord blood transplantation and haploidentical donor transplantation, HSC dose is associated with improved outcomes, whereas insufficient HSC doses are associated with poor outcomes [9, 10].
Source: Experimental Hematology - Category: Hematology Authors: Christina M. Termini, Amara Pang, Destiny M. Batton, John P. Chute Tags: Brief Communication Source Type: research
More News: Cancer & Oncology | Hematology | Stem Cell Therapy | Stem Cells | Transplants | USA Health